Ava Moreno
Sodium-Glucose Co-Transporter-2 (SGLT-2) inhibitors, originally developed for managing diabetes mellitus, have recently garnered attention for their potential anti-cancer properties. This comprehensive review explores the mechanisms of action of SGLT-2 inhibitors and examines emerging novel perspectives on their role in cancer treatment. We delve into the metabolic alterations induced by these inhibitors, their impact on the tumor microenvironment, and their effects on cancer cell proliferation and survival. Furthermore, we discuss recent preclinical and clinical studies highlighting the therapeutic potential of SGLT-2 inhibitors in various cancer types. This article aims to provide a holistic understanding of the current state of research and future directions for SGLT-2 inhibitors in oncology.
ఈ కథనాన్ని భాగస్వామ్యం చేయండి
English 
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi 